Floatz logo

Wu-Cart-007

Hepatosplenic T-cell Lymphoma

Washington University School of MedicineCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Hepatosplenic T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB
ETOPOSIDE
City of Hope Medical Center
Phase 4BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
Ifosfamide
Shandong Provincial Hospital
Phase 4BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB

View all 50 →

Same molecule, other indications

Wu-Cart-007 is also rated in:

T-cell acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →
lymphoblastic lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →
T-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →